References
Baou M, Kohlhaas SL, Butterworth M, Vogler M, Dinsdale D, Walewska R, et al. (2010). Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. Haematologica95 (9): 1510-1518.
Bard JAM, Goodall EA, Greene ER, Jonsson E, Dong KC, Martin A (2018). Structure and Function of the 26S Proteasome. Annual review of biochemistry 87: 697-724.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians68 (6): 394-424.
Cano-Gonzalez A, Mauro-Lizcano M, Iglesias-Serret D, Gil J, Lopez-Rivas A (2018). Involvement of both caspase-8 and Noxa-activated pathways in endoplasmic reticulum stress-induced apoptosis in triple-negative breast tumor cells.Cell death & disease 9 (2): 134.
Ciechanover A (1994). The ubiquitin-proteasome proteolytic pathway. Cell79 (1): 13-21.
Dejure FR, Eilers M (2017). MYC and tumor metabolism: chicken and egg. The EMBO journal36 (23): 3409-3420.
Du Y, Song L, Zhang L, Ling H, Zhang Y, Chen H, et al. (2017). The discovery of novel, potent ERR-alpha inverse agonists for the treatment of triple negative breast cancer. European journal of medicinal chemistry 136:457-467.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer127 (12): 2893-2917.
Fribley A, Zeng Q, Wang CY (2004). Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Molecular and cellular biology24 (22): 9695-9704.
Fribley AM, Evenchik B, Zeng Q, Park BK, Guan JY, Zhang H, et al. (2006). Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa. The Journal of biological chemistry281 (42): 31440-31447.
Harris MA, Miles MA, Shekhar TM, Cerra C, Georgy SR, Ryan SD, et al. (2020). The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice. Cancers12 (5).
Hochstrasser M (1995). Ubiquitin, proteasomes, and the regulation of intracellular protein degradation.Current opinion in cell biology 7 (2): 215-223.
Hu T, Zhang J, Sha B, Li M, Wang L, Zhang Y, et al. (2019). Targeting the overexpressed USP7 inhibits esophageal squamous cell carcinoma cell growth by inducing NOXA-mediated apoptosis. Molecular carcinogenesis 58 (1):42-54.
Itoh A, Nonaka Y, Ogawa T, Nakamura T, Nishi N (2019). Galectin-9 induces atypical ubiquitination leading to cell death in PC-3 prostate cancer cells. Glycobiology29 (1): 22-35.
Jana NR (2012). Protein homeostasis and aging: role of ubiquitin protein ligases. Neurochemistry international 60 (5): 443-447.
Johnson DE (2015). The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors. Endocrine-related cancer22 (1): T1-17.
Kao C, Chao A, Tsai CL, Lin CY, Chuang WC, Chen HW, et al. (2013). Phosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells. Cell death & disease 4:e512.
Kapoor P, Ramakrishnan V, Rajkumar SV (2012). Bortezomib combination therapy in multiple myeloma.Seminars in hematology 49 (3): 228-242.
Kelly KR, Espitia CM, Mahalingam D, Oyajobi BO, Coffey M, Giles FJ, et al. (2012). Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma. Oncogene31 (25): 3023-3038.
Knorr KL, Schneider PA, Meng XW, Dai H, Smith BD, Hess AD, et al. (2015). MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors. Cell death and differentiation22 (12): 2133-2142.
Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, et al. (2010). Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.Cancer research 70 (5): 1970-1980.
Lankes K, Hassan Z, Doffo MJ, Schneeweis C, Lier S, Ollinger R, et al. (2020). Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. Molecular oncology 14 (12):3048-3064.
Liang H, Fan JH, Qiao YL (2017). Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China. Cancer biology & medicine14 (1): 33-41.
Lordick F, Mariette C, Haustermans K, Obermannova R, Arnold D, Committee EG (2016). Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology 27 (suppl 5): v50-v57.
Manasanch EE, Orlowski RZ (2017). Proteasome inhibitors in cancer therapy. Nature reviews. Clinical oncology 14 (7): 417-433.
Mariette C, Piessen G, Triboulet JP (2007). Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. The Lancet. Oncology8 (6): 545-553.
Mimnaugh EG, Xu W, Vos M, Yuan X, Isaacs JS, Bisht KS, et al. (2004). Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Molecular cancer therapeutics3 (5): 551-566.
Minchenko OH, Tsymbal DO, Minchenko DO, Ratushna OO (2016). The role of the TNF receptors and apoptosis inducing ligands in tumor growth. Ukrainian biochemical journal88 (5): 18-37.
Morsi RZ, Hage-Sleiman R, Kobeissy H, Dbaibo G (2018). Noxa: Role in Cancer Pathogenesis and Treatment.Current cancer drug targets 18 (10): 914-928.
Mozos A, Roue G, Lopez-Guillermo A, Jares P, Campo E, Colomer D, et al. (2011). The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma. The American journal of pathology179 (5): 2601-2610.
Niewerth D, Jansen G, Assaraf YG, Zweegman S, Kaspers GJ, Cloos J (2015). Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 18: 18-35.
Nikiforov MA, Riblett M, Tang WH, Gratchouck V, Zhuang D, Fernandez Y, et al. (2007). Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proceedings of the National Academy of Sciences of the United States of America 104 (49): 19488-19493.
Nilsson JA, Cleveland JL (2003). Myc pathways provoking cell suicide and cancer. Oncogene22 (56): 9007-9021.
Oakes SA, Papa FR (2015). The role of endoplasmic reticulum stress in human pathology. Annual review of pathology 10: 173-194.
Ooko E, Kadioglu O, Greten HJ, Efferth T (2017). Pharmacogenomic Characterization and Isobologram Analysis of the Combination of Ascorbic Acid and Curcumin-Two Main Metabolites of Curcuma longa-in Cancer Cells. Frontiers in pharmacology 8: 38.
Pelengaris S, Khan M, Evan G (2002). c-MYC: more than just a matter of life and death. Nature reviews. Cancer 2 (10): 764-776.
Piperdi B, Walsh WV, Bradley K, Zhou Z, Bathini V, Hanrahan-Boshes M, et al. (2012). Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer7 (6): 1032-1040.
Ramirez PT, Landen CN, Jr., Coleman RL, Milam MR, Levenback C, Johnston TA, et al. (2008). Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer. Gynecologic oncology 108 (1): 68-71.
Richardson P (2003). Clinical update: proteasome inhibitors in hematologic malignancies. Cancer treatment reviews 29 Suppl 1: 33-39.
Rosekrans SL, Heijmans J, Buller NV, Westerlund J, Lee AS, Muncan V, et al. (2015). ER stress induces epithelial differentiation in the mouse oesophagus. Gut64 (2): 195-202.
Sato A, Asano T, Isono M, Ito K, Asano T (2014). Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells. BMC urology 14: 71.
Sato A, Asano T, Ito K, Asano T (2012). Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells. The Journal of urology 188 (6): 2410-2418.
Sato A, Asano T, Okubo K, Isono M, Asano T (2017). Ritonavir and ixazomib kill bladder cancer cells by causing ubiquitinated protein accumulation. Cancer science108 (6): 1194-1202.
Shirley M (2016). Ixazomib: First Global Approval. Drugs 76 (3): 405-411.
Soldatenkov VA, Prasad S, Voloshin Y, Dritschilo A (1998). Sodium butyrate induces apoptosis and accumulation of ubiquitinated proteins in human breast carcinoma cells. Cell death and differentiation 5 (4): 307-312.
Sosa Seda IM, Mott JL, Akazawa Y, Barreyro FJ, Bronk SF, Kaufmann SH, et al. (2010). Noxa mediates hepatic stellate cell apoptosis by proteasome inhibition.Hepatology research : the official journal of the Japan Society of Hepatology 40 (7): 701-710.
Wirth M, Stojanovic N, Christian J, Paul MC, Stauber RH, Schmid RM, et al. (2014). MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib.Nucleic acids research 42 (16): 10433-10447.
Yoshida GJ (2018). Emerging roles of Myc in stem cell biology and novel tumor therapies. Journal of experimental & clinical cancer research : CR 37 (1):173.
Yue D, Sun X (2019). Ixazomib promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer cells. Cancer biology & therapy 20 (3):284-294.
Zhang L, Liu P, Chen H, Li Q, Chen L, Qi H, et al. (2016). Characterization of a selective inverse agonist for estrogen related receptor alpha as a potential agent for breast cancer. European journal of pharmacology 789:439-448.
Zhang L, Zhu Y, Cheng H, Zhang J, Zhu Y, Chen H, et al. (2019). The Increased Expression of Estrogen-Related Receptor alpha Correlates with Wnt5a and Poor Prognosis in Patients with Glioma. Molecular cancer therapeutics18 (1): 173-184.
Zhao J, He YT, Zheng RS, Zhang SW, Chen WQ (2012). Analysis of esophageal cancer time trends in China, 1989- 2008. Asian Pacific journal of cancer prevention : APJCP13 (9): 4613-4617.
Zhao Y, Foster NR, Meyers JP, Thomas SP, Northfelt DW, Rowland KM, Jr., et al. (2015). A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 10 (1):172-180.